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Introduction: The antiretroviral treatment paradigm for human immunodeficiency virus-1 
(HIV-1) infection has undergone a significant change with the addition of a new class of therapeutic 
agents targeting HIV-1 integrase (IN). IN inhibitors prevent the integration of viral DNA into 
the human genome and terminate the viral life cycle. As the first member of this new class of 
anti-HIV drugs, raltegravir has shown promising results in the clinic.
Aims: To review the emerging evidence for the use of the IN inhibitor raltegravir in the 
treatment of HIV-1 infection.
Evidence review: Strong evidence shows that raltegravir is effective in reducing the viral 
load to less than 50 copies/mL and increasing CD4 cell count in treatment-experienced patients 
with triple-drug class-resistant HIV-1 infection. Substantial evidence also indicates that while 
raltegravir is able to achieve treatment response in patients with drug-resistant HIV-1, it is 
susceptible to development of resistance. Raltegravir should be used with at least one other active 
drug. In addition to its use in salvage therapy upon failure of first-line antiretroviral treatment, 
a raltegravir-based treatment regimen may also be effective as initial therapy. Substantial 
evidence also shows that raltegravir-based treatment regimen is well tolerated with minimal 
clinically severe adverse events and toxicities. Modeling studies suggest a cost-effectiveness 
of US$21,339 per quality-adjusted life year gained with raltegravir use, though further direct 
evidence on quality of life and cost-effectiveness is needed.
Place in therapy: Raltegravir shows significant and sustained virologic and immunologic 
response in combination with other antiretrovirals in treatment-experienced HIV-1 infected 
patients who show evidence of viral replication or multidrug-resistant HIV-1 strains, without 
any significant tolerability issues.
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Core evidence place in therapy summary for raltegravir as an antiretroviral drug in 
HIV-1 patients
Outcome measure Evidence Implications
Disease-oriented evidence
Reduction in viral load to less than 
50 copies/mL
Clear Sustained virologic response can be 
achieved in treatment-experienced 
and multidrug-resistant Hiv-1 
patients. Effective alternative for 
salvage therapy.
increase in CD4 cell count Clear increase in CD4 immune cell 
count with addition of raltegravir 
in triple-class drug-resistant Hiv-1 
patients. Effective alternative for 
salvage therapy.
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Scope, aims, and objectives
Raltegravir (MK-0518, Isentress®; Merck & Co., Whitehouse 
Station, NJ) was approved by the US Food and Drug 
Administration (FDA) in October, 2007 and granted European 
approval in January, 2008 as the first human immunodeficiency 
virus-1 (HIV-1) integrase (IN) inhibitor for the treatment of 
HIV-1 infection in treatment-experienced patients. It differs 
from other currently available antiretrovirals in that it targets 
a distinct step in the viral life cycle namely, integration into 
the human genome. Raltegravir has demonstrated clinical 
efficacy in treatment-experienced patients, who showed 
evidence of viral replication or multidrug-resistant HIV-1 
strains, and has resulted in sustained suppression of virologic 
load. Studies in animals and healthy volunteers have shown 
minimal clinically significant drug interactions. This has 
generated great optimism of overcoming the challenges with 
current antiretroviral treatment.
This article reviews the evidence for the use of raltegravir 
for the treatment of HIV-1 infection in treatment-experienced 
patients, provides an assessment of the benefits and challenges 
with the use of raltegravir, and considers its implications for 
IN inhibitors next in line. Use in pediatric patients is excluded 
as the safety and efficacy of raltegravir in this population 
have not been established.
Methods
Relevant publications including peer-reviewed articles, 
letters and case reports were identified by searching the 
following electronic databases. Initial search was performed 
in October, 2008 and updated in February, 2009. The search 
strategy included the following keywords: ‘Raltegravir’ OR 
‘MK-0581’ OR ‘Isentress’. In addition to literature on clinical 
findings, relevant publications regarding the pharmacology 
of raltegravir were also reviewed.
•  Pubmed, http://www.ncbi.nlm.nih.gov/sites/entrez. 
Search strategy: “MK 0518”[Substance Name] OR 
“MK 0518”[All Fields] OR “raltegravir”[All Fields] and 
limited to English-language results.
(Continued)
Outcome measure Evidence Implications
virologic failure Substantial Low genetic barrier for 
developing integrase mutations. 
Raltegravir should be used with at 
least one other active drug.
Reduction in incidence of AiDS-
related infections
Limited No reduction in risk of 
AiDS-related infections with 
raltegravir use.
Patient-oriented evidence
Decrease in adverse events Substantial No statistically significant 
difference in the incidence of 
adverse events with raltegravir 
use.
Reduction in toxicity Substantial No statistically significant 
difference in the incidence of 
adverse events with raltegravir 
use.
Reduction in drug–drug and 
drug–food interactions
Clear No clinically significant 
interactions. No dosage 
adjustments recommended, 
except for coadministration with 
rifampin.
Reduction in mortality Limited No incremental improvement in 
survival with raltegravir use.
improvement in quality of life No evidence
improvement in patient compliance No evidence
Economic evidence
Cost-effectiveness as an 
antiretroviral agent in Hiv-1 patients
Limited US$21,339 per quality-adjusted life 
year gained with raltegravir use.Core Evidence 2009:4 133
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•  Ovid MEDLINE(R), http://ovidsp.tx.ovid.com/spa/
ovidweb.cgi. Search limited to English-language 
results.
•  National Library of Medicine (NLM) Gateway, http://
gateway.nlm.nih.gov/gw/Cmd.
•  Cochrane Database of Systematic Reviews and Cochrane 
Central Register of Controlled Trials, http://www.
cochrane.org/.
•  EBM Reviews – NHS Economic Evaluation Database, 
Database of Abstracts of Reviews of Effects and Health 
Technology Assessment, http://ovidsp.tx.ovid.com/spa/
ovidweb.cgi.
•  NIHR Health Technology Assessment programme, 
http://www.ncchta.org/.
•  National Guideline Clearing House, http://www.guideline.
gov/.
•  Essential Evidence Plus, http://www.essentialevidenceplus.
com/.
•  Clinical Evidence (BMJ), http://clinicalevidence.bmj.
com/.
•  International Pharmaceutical Abstracts, http://ovidsp.
tx.ovid.com/spa/ovidweb.cgi.
A total of 156 relevant records were retrieved from 
Pubmed/Medline/NLM gateway. Eleven records were 
retrieved from Cochrane Central Register of Controlled 
Trials. Six related guidelines were identified from the 
National Guideline Clearinghouse. No matches were found 
in the other database searches. Records were manually 
reviewed, and a total of 138 records including duplicate 
records, nonsystematic reviews, animal studies and in vitro 
studies were excluded (Table 1).
Scientific abstracts from relevant meetings and conferences 
were identified by searching the following websites:
•  BIOSIS Previews, http://www.isiknowledge.com/.
•  Conference on Retroviruses and Opportunistic Infections, 
http://www.retroconference.org/ (1997–2009).
•  Interscience Conference on Antimicrobial Agents and 
Chemotherapy, http://www.icaac.org/.
•  International AIDS Society Conference on HIV 
Pathogenesis, Treatment and Prevention and Interna-
tional AIDS Conference, http://www.iasociety.org/ 
(2001–2008).
This retrieved a total of 101 records. After excluding 
records on animal studies, in vitro studies, duplicate 
publications presented in full papers and studies that did not 
investigate the clinical use of raltegravir, a total of 19 records 
were included for discussion. In the absence of level 1 
evidence specifically evaluating the therapeutic efficacy of 
raltegravir, outcomes from original level 2 or 3 studies were 
included for discussion for clinical evidence.
Disease overview
HIV is the causative pathogen of the global pandemic, 
acquired immunodeficiency syndrome (AIDS). There were 
an estimated 33 million people living with HIV worldwide 
in 2007, with approximately one million in the United 
States. The estimated number of deaths among adults and 
children due to AIDS globally was approximately two 
million in 2007.1 In the recent years, there has been major 
progress in terms of developing newer antiretrovirals and 
expanding access to treatment. This has resulted in a better 
prognosis for patients with AIDS despite the high disease 
incidence levels.
HIV is perhaps one of the most adaptive and evasive 
pathogens. Upon exposure, the retrovirus binds to the 
human T lymphocytes. HIV fuses into the host and releases 
its genetic material in the form of RNA. This step is called 
fusion. Viral RNA is then converted into proviral DNA 
by reverse transcription catalyzed by the enzyme reverse 
transcriptase (RT). This is followed by insertion of the 
proviral DNA into the host genome by IN–integration step. 
The viral genome is transcribed using host machinery, and 
viral proteins are processed by viral protease enzyme. Newly 
assembled particles are released from the cell by budding. 
Ultimately, viral replication causes depletion of the human 
immune system, leaving the infected individual susceptible 
to opportunistic infections such as pulmonary infection, 
gastrointestinal infection, neurological conditions, and 
tumors and malignancies.
Treatment with antiretroviral agents can provide virologic 
suppression, immunologic response, and other disease-related 
Table 1 Evidence base included in the review
Category Number of records
Full papers Abstracts
initial search 167 101
Records excluded 138 82
Records included 29 19
Level 1 clinical evidence 0 0
Level 2 clinical evidence 14 6
Level  3 clinical evidence 15 11
Trials other than RCT 13 11
Case studies 2 0
Economic evidence 0 2
Abbreviation: RCT, randomized, controlled trials.Core Evidence 2009:4 134
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benefits. Recent guidelines recommend antiretroviral 
therapy for individuals with symptomatic HIV disease. For 
asymptomatic individuals, treatment with antiretroviral 
agents should be initiated before the CD4 cell count decreases 
to less than 350 per µL. For asymptomatic individuals with 
CD4 cell count more than 350 per µL, individualized therapy 
depending on comorbidities and risk of disease progression 
is recommended.2 There is no clear evidence to support 
treatment initiation in primary HIV-1 infection.
Current therapy options
The current standard of treatment, the highly active 
antiretroviral treatment (HAART), consists of a cocktail of 
antiretroviral drugs, which includes nucleoside RT inhibitors, 
nonnucleoside RT inhibitors, protease inhibitors, and/or a 
fusion inhibitor. These antiretroviral agents target various 
stages in the viral life cycle. The goal of antiretroviral therapy 
is to reduce and maintain an HIV-1 RNA level of less than 
50 copies/mL, regardless of previous treatment experience.2 
A randomized multicenter, open-label trial study by the AIDS 
clinical trials group compared three treatment regimens: 
efavirenz, a nonnucleoside RT inhibitor, plus two nucleoside 
RT inhibitors; ritonavir boosted lopinavir plus two nucleoside 
RT inhibitors; and efavirenz plus lopinavir/ ritonavir without 
nucleoside RT inhibitors.3 Nonnucleoside RT inhibitor-based 
treatment regimens showed durable virologic suppression to 
less than 50 copies/mL with longer time to treatment failure 
at 96 weeks. On the other hand, increase in basleine CD4 
cell count was greater in patients taking lopinavir/ritonavir 
plus two nucleoside RT inhibitors. Other protease inhibitor-
based regimens have also demonstrated similar outcomes to 
lopinavir/ritonavir treatment. The current recommendations 
for initial therapy are two nucleoside RT inhibitors plus 
efavirenz or a protease inhibitor boosted with ritonavir. 
Efavirenz is not recommended for women in early pregnancy. 
Nevirapine is another alternative for a nonnucleoside RT 
inhibitor-based regimen. Recommended ritonavir boosted 
protease inhibitors include lopinavir, atazanavir, fosampre-
navir, darunavir or saquinavir. Tenofovir/emtricitabine or 
abacavir/lamivudine are the recommended nucleoside RT 
inhibitor combinations for initial therapy. The choice of the 
treatment regimen is influenced by various factors such as 
pill burden, toxicity, and adverse effects, drug interactions, 
comorbid illness, and presence of primary drug resistance.
Three new antiretrovirals have been recently approved. 
These newer drugs are active against drug-resistant 
HIV-1 viral strains and approved for use as salvage therapy 
in treatment-experienced patients with treatment failure 
and/or multidrug resistance. Raltegravir is an IN inhibitor. 
Maraviroc (SelzentryTM; Pfizer, New York, NY) is a CCR5 
co-receptor antagonist. It is indicated for use only in patients 
with CCR5-tropic virus. It does not show efficacy in mixed 
or dual tropism viruses and requires a tropism assay before 
prescribing maraviroc treatment. Maraviroc is metabolized 
by cytochrome P450 enzymes and, therefore, its dosing 
depends on the effect of coadministered drugs on these 
enzymes.4 Etravirine (IntelenceTM; Tibotec, Bridgewater, NJ) 
is a nonnucleoside RT inhibitor. It is recommended for use in 
patients who are resistant to currently-used nonnucleoside RT 
inhibitors. Etravirine is also metabolized by the cytochrome 
P450 enzymes and suffers from potential drug interactions, 
especially with certain protease inhibitors.5,6 Raltegravir is 
recommended for use in combination therapy upon failure of 
first-line treatment regimen with nonnucleoside RT inhibitor 
or protease inhibitor or in the case of multidrug resistance. 
Initial therapy with raltegravir should be considered only 
under rare circumstances. With the use of raltegravir and 
the other newer antiretrovirals maraviroc and etravirine, 
viral load suppression to less than 50 copies/mL can be 
achieved even in patients with virologic failure and multidrug 
resistance. Raltegravir offers the additional advantages of 
improved tolerability and safety profiles.
Unmet needs
Despite the availability of effective antiretroviral agents, 
therapeutic needs for effective disease management are still 
unmet. The limitations of existing antiretrovirals include 
severe drug toxicities and interactions, adverse events, the 
emergence of multidrug resistance strains and eventual 
treatment failure.7 Long-term treatment with antiretrovirals 
can result in toxicitites such as nephrotoxicity, hepatotoxicity 
and cardiovascular effects. In addition to drug toxicities, 
antiretroviral therapy can have a wide range of adverse 
effects. Mild adverse events include nausea, diarrhea, 
fatigue, and headache, while more serious adverse effects 
include peripheral neuropathy, hepatotoxicity, lipodystrophy, 
hypersensitivity, and skin rashes.8
Treatment of HIV infection involves a combination 
of various antiretroviral agents. In addition, concomitant 
medications for opportunistic infections and other comorbid 
conditions are also often included in this cocktail. 
Several of the existing antiretrovirals inhibit or induce 
various drug-metabolizing enzymes. This can affect the 
pharmacokinetics and plasma concentrations of concomitantly 
administered drugs in an advantageous or undesirable way.9 
Choice of treatment should therefore consider all possibilities Core Evidence 2009:4 135
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of drug interactions in order to minimize suboptimal therapy 
and toxic effects.
Another area of growing concern is the emergence of 
multidrug-resistant viral strains. Due to the inherent genetic 
adaptability of the retrovirus, drug-resistant viral strains 
rapidly emerge, leading to treatment failure. In addition to 
treatment-experienced patients who are drug-resistant and 
unresponsive, there is also an increase among treatment-
naïve patients who are infected with multidrug-resistant 
viral strains.10 Antiretroviral therapy therefore must include 
at least two fully active drugs against the multidrug-resistant 
viral strains.
Treatment adherence is also another critical factor that 
determines the success of antiretroviral therapy. Drug-related 
factors that influence patient compliance include tolerability 
of medication, dosing frequency, dietary restrictions, 
pill burden, and cost.11 Improving regimen convenience 
will contribute to greater adherence to therapy and lesser 
likelihood of drug resistance.12,13 It is hoped that these unmet 
needs would be addressed by newer classes of antiretrovirals 
such as the IN inhibitors.
Pharmacology of raltegravir
Raltegravir inhibits the strand transfer function of HIV-1 IN with 
potency in the low nanomolar range. An apparent half-maximal 
inhibitory concentration (IC50) of 2–7 nM for strand transfer 
inhibition was determined by in vitro experiments using 
purified IN enzyme. The compound blocks the stable insertion 
of the viral DNA into the human genome and hence sustained 
viral replication and infectivity. Consequently, raltegravir 
also exhibits potent antiviral activity in cell-based assays. In a 
multicycle replication assay, it blocked HIV-1 replication with 
an IC95 value of 19 ± 14 nM and 33 ± 23 nM when tested in the 
presence of 10% fetal bovine serum and 50% normal human 
serum, respectively.14,15 Raltegravir is effective against a panel 
of 15 primary HIV-1 isolates of 6 subtypes. It also exhibits 
potent in vitro activity against multidrug-resistant HIV-1 
clinical isolates, HIV-2 and simian immunodeficiency virus.14,16 
Quantitative polymerase chain reaction (PCR) studies revealed 
that HIV infected cells treated with raltegravir showed an 
increase in two-long terminal repeat circular DNA, while HIV 
cDNA synthesis was unaffected. Formation of circular DNA is 
a result of accumulation of viral cDNA and is indicative of a 
defective HIV integration into host genome. Studies regarding 
the effect of higher doses of raltegravir on the rate of decay of 
latent viral reservoirs are ongoing.
Raltegravir shows greater than 1,000-fold selectivity 
for HIV-1 IN over several related Mg2+-dependent enzymes 
such as hepatitis C virus (HCV) polymerase, HIV RT, 
HIV RNase-H, and human α-, β- and γ-polymerases 
(IC50 values  50 µM). It is also inactive at concentrations 
of less than 10 µM against various enzymes, channels and 
receptors.15 Raltegravir does not inhibit any of the major 
cytochrome P450 enzymes such as CYP1A2, CYP2C9, 
CYP2D6 or CYP3A4 with IC50 values  50 µM. Binding 
affinity to hERG channels was greater than 50 µM. This 
suggests minimal off-target effects.
Pharmacokinetics and metabolism
The pharmacokinetic profile and metabolism of raltegravir 
were studied in three preclinical species: Sprague–Dawley 
rats, dogs, and rhesus monkeys. Raltegravir was dosed orally 
as different salt forms using 1% methyl cellulose as vehicle. 
Better bioavailability with a linear dose-proportional area 
under the curve (AUC) was obtained with the potassium salt 
of raltegravir. It exhibited moderate to high binding to plasma 
proteins. Raltegravir is stable in liver microsomes. It is 
primarily metabolized via the glucouronidation pathway by the 
enzyme, uridine diphosphate (UDP)-glucuronosyl transferase 
isoenzyme 1A1 (UGT1A1). In vivo metabolism studies using 
radiolabeled raltegravir also confirmed glucouronidation as 
the major route of metabolism.
The safety, tolerability and pharmacokinetics of raltegravir 
in humans were evaluated in three phase I studies. Single-
dose escalation studies over a dose range of 10–1200 mg of 
raltegravir demonstrated approximately dose-proportional 
increases in AUC and plasma concentrations.17 Raltegravir 
was rapidly absorbed, and time to peak plasma concentrations 
were between 0.5 to 1.3 h. A biphasic decline in plasma 
concentrations was observed with an apparent half-life 
of initial phase of 1 h and a terminal phase half-life of 
7–12 h. Raltegravir dose of 200 mg or higher achieved 
C12 h concentrations greater than the protein-adjusted 
IC95 value of 33 nM. Key pharmacokinetic parameters 
of raltegravir at 200 and 400 mg doses are summarized 
in Table 2. The fraction unbound to plasma proteins as 
determined by in vitro studies is 17%.15 Multiple dosing 
studies showed little to modest accumulation of raltegravir. 
The accumulation ratios for maximum concentration (Cmax) 
and AUC0–12 h ranged between 0.7 and 1.2, while that for 
C12 h ranged between 1.2 and 1.6. Overall exposure profile 
was similar between male and female subjects, though 
comparatively lower C12 h values and longer apparent terminal 
elimination half-lives were observed in female subjects.
Substantial amounts of radioactivity were recovered 
from urine (32%) and feces (51%) after a single oral dose Core Evidence 2009:4 136
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of 200 mg of [14C]-raltegravir in healthy male volunteers18 
Raltegravir was eliminated rapidly, and the majority of the 
administered dose was recovered within 24 h. Metabolite 
profiling identified raltegravir as the unchanged drug (9%) 
and its glucuronide form (23%) as the major components in 
the urinary fraction. Raltegravir is eliminated via the fecal 
route as the parent unchanged compound, likely derived 
from the hydrolysis of its glucuronide form secreted into 
bile. Raltegravir was also identified as the major circulating 
form in the plasma (70%). Raltegravir was stable in liver 
microsomes and was not metabolized. Using cDNA 
expressed UGTs and specific enzyme inhibitors, UGT1A1 
isoform was identified as the major metabolizing enzyme 
of raltegravir.
Clinical evidence with raltegravir
Clinical efficacy of raltegravir has been demonstrated in 
treatment-naïve as well as treatment-experienced patient 
populations. Evidence regarding disease-oriented outcomes 
such as virologic response, immunologic response, 
emergence of resistance, treatment failure and incidence of 
AIDS-related events, as well as patient-oriented outcomes 
such as drug toxicity, adverse events, and drug interactions 
are presented here.
virologic response in Hiv-1-infected 
treatment-naïve patients
The short-term antiretroviral activity and safety of raltegravir 
has been explored in a multicentered, double-blinded, 
randomized, placebo-controlled study.19 Four different doses 
of raltegravir (100, 200, 400, and 600 mg) given twice daily 
for 10 days as monotherapy were compared with placebo. 
After 10 days of treatment, raltegravir showed significant 
virologic response with a decrease in baseline HIV-1 RNA 
level of 2 log10 copies/mL at all four doses, compared to 
a decrease of 0.2 log10 copies/mL with placebo treatment. 
At least 50% of the patients treated with raltegravir as 
a single agent achieved HIV-1 RNA levels less than 
400 copies/mL. No serious adverse events were observed. 
Though monotherapy with raltegravir proved effective in 
reducing viral loads, there was a higher risk for development 
of resistance. Therefore, the efficacy of raltegravir was 
compared against that of efavirenz as part of combination 
therapy with tenofovir and lamivudine in treatment-naïve 
patients.20 Raltegravir, at all four doses, along with the 
combination therapy resulted in sustained reduction in HIV-1 
RNA levels. By week 4 and week 8, HIV-1 RNA levels were 
rapidly reduced to less than 50 copies/mL in a significant 
proportion of patients treated with raltegravir compared to 
those taking efavirenz. These reductions in viral load were 
maintained through 48 weeks (Figure 1). However, virologic 
failure occurred in 3% of patients with the emergence of 
resistance mutations. The adverse events observed during 
the study were similar in patients receiving either treatment. 
This study demonstrated rapid and sustained suppression of 
plasma viremia. The overall antiviral efficacy of raltegravir 
at 24 and 48 weeks was similar to that of efavirenz, although 
raltegravir achieved more rapid reduction in viral load.
Recent data on the efficacy of raltegravir after 96 weeks 
of combination therapy in treatment-naïve patients shows 
sustained antiviral effects similar to the 48-week data. 
No new resistance mutations emerged after 48 weeks of 
treatment. Though 100 and 200 mg raltegravir twice daily 
were successful in achieving viral suppression through 
Table 2 Clinical pharmacokinetic profile of raltegravir in healthy volunteers following fasted administration of oral dose
Parameter
Dose (mg)
Single-dose escalation study Multiple-dose escalation 
study (q12 h)
400 800 400
C12 h (nM) 81.3 206.9 200.6
AUC0–12 h (µM.h) 24.61 63.11 28.68
Cmax (µM) 10.63 24.67 11.18
Tmax (h) 1.0 1.3 1.0
T1/2–α (h) 1.07 1.01 1.07
T1/2–β (h) 6.9 12.4 10.7
Fraction eliminated unchanged 
in urine
9.95 9.77 11.4
Renal clearance (mL/min) 60.88 48.52 60.5
Abbreviations: AUC, area under the curve; Cmax, maximum concentration.Core Evidence 2009:4 137
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48 weeks, 400 mg dose was administered to all patients after 
48 weeks. In general, raltegravir appeared well tolerated 
with no serious side effects at 96 weeks of combination 
therapy.21
In a large, randomized phase III study STARTMRK, 
the safety and efficacy of raltegravir-based regimens were 
compared against efavirenz-based treatment regimens in 
treatment-naïve patients.22,23 The optimized background 
therapy (OBT) in both treatment groups included tenofovir 
and emtricitabine. At week 48, raltegravir-based treatment 
demonstrated noninferior antiretroviral activity, with 86% of 
patients taking raltegravir achieving a viral load of less than 
50 copies/mL compared to 82% of patients on efavirenz. 
Raltegravir treatment also increased CD4 cell count more than 
efavirenz treatment with significantly fewer adverse effects. 
Further subgroup analysis demonstrated consistent virologic 
and immunologic response with raltegravir treatment across 
various demographic and baseline prognostic factors such as 
baseline HIV-1 RNA level and baseline CD4 cell count.
virologic response in treatment-experienced 
Hiv-1-infected patients
Efficacy of raltegravir in combination with OBT in 
treatment-experienced patients was evaluated in a multicenter, 
dose-ranging, randomized, placebo-controlled phase II 
study.24 Treatment-experienced patients included in the study 
had advanced HIV-1 infection with treatment failure, with 
triple-class drug-resistant virus, and with a limited number 
of effective treatment options. Raltegravir in combination 
with OBT, at doses of 200, 400, or 600 mg twice daily, was 
compared with placebo. As observed in treatment-naïve 
patients, raltegravir treatment resulted in a decrease of 2 log10 
copies/mL in HIV-1 RNA levels from baseline viral load 
within two weeks of initiation of treatment. By week 24, 
a reduction in HIV-1 RNA levels to less than 50 copies/mL 
was achieved in 70%, 64.5%, and 62.5% of patients in the 
treatment groups with 200, 400, and 600 mg of raltegravir, 
respectively.
Identical, randomized phase-III international trials – 
BENCHMRK-I and BENCHMRK-II – conducted in 
different geographic regions also demonstrated efficacy 
of raltegravir compared against placebo in combination 
with OBT. The goal of these studies was to evaluate the 
safety and efficacy of raltegravir at a dose of 400 mg 
in a larger population of HIV-1 infected patients, with 
triple-class resistance mutations in whom previous 
antiretroviral therapy had failed.25 In the BENCHMRK-I 
trial, considering lack of efficacy as treatment failure, HIV-1 
RNA levels below 50 copies/mL were achieved in 79.5% 
of patients who received raltegravir compared with 42.5% 
of placebo recipients. Similar results were obtained in the 
BENCHMRK-II trial; HIV-1 RNA levels below 50 copies/mL 
were achieved in 79.7% of raltegravir recipients compared 
with 43.6% of placebo recipients. In the combined 
analysis of the two trials, HIV-1 RNA levels at week 48 
were reduced below 50 copies/mL in 62.1% of raltegravir 
recipients compared with 32.9% of placebo recipients, 
considering noncompletion as treatment failure (Figure 2). 
85
83
88
88
97
85
98
90
75 80 85 90 95 100
39
40
41
40
n
<400 
copies/ml
<50 
copies/ml
600 mg
400 mg
200 mg
100 mg
Dose
% of Treatment-naïve patients
HIV-1 RNA levels
Figure 1 Efficacy of raltegravir as part of combination therapy in treatment-naïve patients at week 48 of treatment.Core Evidence 2009:4 138
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These studies have provided sufficient evidence that raltegravir 
in combination with OBT provides better viral suppression 
than OBT alone in triple-class drug-resistant HIV-1-infected 
patients. Recent 96-week results from the BENCHMRK 
1&2 phase III trials further demonstrate sustained and 
superior antiretroviral and immunological response with 
raltegravir plus OBT compared to OBT alone in triple-class 
drug-resistant HIV-1 patients. 58% of raltegravir recipients 
compared with 26% of placebo recipients had HIV-1 RNA 
less than 50 copies/mL.26
The effect of raltegravir on the dynamics of viral 
production is rather surprising. Monotherapy with raltegravir 
decreases the first-phase viral production arising from 
infected CD4 T cells. In combination with other antiretroviral 
agents, it resulted in rapid and extended first-phase decay 
and reduced the viral load at which the second-phase of 
viral production commenced.27 The second-phase of viral 
production is thought to be influenced by long-lived infected 
cells and dissociating viruses from dendritic cells. Since 
raltegravir targets the integration step, it is not expected 
to act on the second-phase of viral production. The rapid 
decay dynamics observed with raltegravir treatment in all the 
clinical studies are thought to be a consequence of the stage 
in the viral life cycle it inhibits and not necessarily due to 
its greater efficacy.28 Using mathematical models to analyze 
viral decay dynamics, it has been proposed that more rapid 
decay in viremia is achieved by inhibitors that act late in the 
viral life cycle.
virologic response in multidrug resistant 
Hiv-1 infected patients
Patients infected with multidrug-resistant viral strains are 
currently treated with an enfuvirtide-based treatment regimen. 
Owing to its ease of administration and improved long-term 
tolerability over the injectable enfuvirtide, raltegravir is being 
considered as an alternative in salvage therapy. A cohort 
of patients who were treated with enfuvirtide for a median 
of 25 months and who had plasma HIV-1 RNA levels less 
than 50 copies/mL switched to raltegravir.29 Concomitant 
antiretrovirals which included nucleoside RT inhibitors 
and protease inhibitors in all patients, and nonnucleoside 
RT inhibitors in few patients, were left unchanged. After 
a median follow-up time of seven months, all but one 
patient had HIV-1 RNA levels less than 50 copies/mL. 
Only mild and no severe adverse events were observed. 
In another randomized, noninferiority trial, patients with 
triple-class resistant HIV-1 infection were randomized 
between enfuvirtide-based regimen and enfuvirtide-based 
regimen followed by switch to raltegravir-based regimen. 
At week 24, 89% of patients in both treatment groups had 
plasma RNA levels less 50 copies/mL, suggesting a noninfe-
rior antiviral activity of raltegravir compared to enfuvirtide.30 
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Changing from enfuvirtide to raltegravir in a salvage therapy 
regimen was well tolerated, and effective virologic sup-
pression was sustained. In addition, raltegravir offers the 
advantages of improved patient compliance to treatment 
regimen and economic viability. Randomized, multicenter, 
controlled noninferiority trials SWITCHMRK 1&2 evaluated 
the outcome of switching to raltegravir-based regimen in 
HIV-1 patients who had undetectable viral loads on a lopina-
vir/ritonavir-based treatment regimen. Raltegravir treatment 
was well tolerated and resulted in improved lipid parameters. 
However, switching from stable lopinavir/ritonavir-based 
treatment regimen to raltegravir-based regimen did not 
demonstrate noninferior outcome at week 24.31 This study 
included patients who had failed prior therapies who may have 
accumulated high level resistance to the other antiretrovirals 
used in the treatment regimen. In such conditions, switching 
from an active boosted protease inhibitor with a high genetic 
barrier to a drug with low genetic barrier did not yield a 
superior therapeutic outcome.
Efficacy of raltegravir in HIV-2- 
infected patients
Raltegravir inhibited replication of HIV-2 isolates in 
CEMx174 cells with an IC95 value of 6.3 nM in the presence 
of 10% fetal bovine serum.16 Sequence analysis revealed 
naturally occurring polymorphisms in 38% of HIV-2 IN 
residues. Interestingly, polymorphisms in HIV-2, at residues 
implicated in HIV-1 resistance to raltegravir, did not affect 
its phenotypic susceptibility to IN inhibitors. Also, the 
key primary mutations that confer high level resistance to 
raltegravir were absent in HIV-2, though secondary mutations 
were found.32
A short-term virologic efficacy study in a HIV-2 infected 
patient demonstrated response with raltegravir treatment. 
Two months of treatment with raltegravir in combination with 
abacavir, azidovudine and darunavir/ritonavir in the heavily 
pretreated drug-resistant HIV-2 patient resulted in over 500-fold 
reduction in viral load. However, resistance mutations (N155H) 
emerged rapidly.33 HIV-2 differs substantially from HIV-1 in 
its structure and sequence. It is less susceptible to antiretroviral 
agents and hence, patients infected with HIV-2 have limited 
therapeutic options. In the light of these findings, raltegravir and 
the class of IN inhibitors represent a novel therapeutic option 
for adjuvant therapy in HIV-2 infected patients.
immunologic response
In the BENCHMRK trials, results at week 48 also demonstrated 
significant increase in baseline CD4 cell count with 
raltegravir-based treatment regimen (109 cells/mm3) in 
comparison to the control group (45 cells/mm3).25 Even at 
96 weeks of treatment, the results were consistent with a 
sustained and superior immunologic response with mean 
increase in baseline CD4 cell count being 123 cells/mm3 in 
raltegravir recepients versus 49 cells/mm3 in control group.26
In addition to the increase in CD4 immune cell count, 
occurrence of immune reconstitution syndrome has also 
been reported. During initial treatment with raltegravir, rapid 
reduction of viral load and increase in CD4 cell count could 
result in immune reconstitution syndrome in some patients. 
This is an inflammatory response to residual opportunistic 
infections, and monitoring and treatment may be necessary. 
Frequency of rash of mild to moderate intensity was slightly 
higher in raltegravir treatment group. Other less common 
immune-related adverse reaction was hypersensitivity in less 
than 2% of raltegravir recepients.
Resistance and treatment failure
The low genetic barrier of HIV-1 IN compromises the 
susceptibility of viruses to raltegravir. Rapid development 
of resistance has been observed in both in vitro and clinical 
studies. Resistance to raltegravir arises due to a combination 
of few primary mutations and several additional secondary 
mutations. Several IN residues implicated in the development 
of drug resistance have been identified through resistance 
passage studies, and the resistance profile of raltegravir has 
been studied using HIV-1 containing these IN mutations.15 
Mutations at residues N155 and Q148 lead to greater than 
10-fold shift in raltegravir sensitivity in single-infectivity 
assays. Several other single mutations contribute to 
raltegravir resistance, but to a lesser extent. Combination 
of a key mutation with other secondary mutations results 
in high level resistance. Double mutants such as Q148H/
R/G140S resulted in greater than 400-fold decrease in 
susceptibility to raltegravir. Similarly, N155H/E92Q results 
in a 13- to 64-fold drug resistance. A novel mutation, L68V 
is found to be specifically associated with E92Q mutation in 
clinical isolates. L68V/Q148R mutant was 53-fold resistant 
to raltegravir.34 A summary of the raltegravir resistance 
profile due to various key and minor mutations is shown in 
Figure 3.
Subgroup analysis of the data from BENCHMRK studies 
found that at 48 weeks of treatment with raltegravir in 
combination with OBT, 23% of the drug recipients suffered 
virologic failure.35 IN genotyping done at baseline and after 
treatment failure revealed the presence of mutations in the IN 
gene. Mutations at one of the three residues – N155, Q148, or Core Evidence 2009:4 140
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Y143 – resulted in high level resistance. Additional secondary 
mutations at residues T66, L74, and E92 have also been found. 
Similar results were obtained in another cohort of multidrug-
resistant HIV-1-infected patients, who suffered from virologic 
failure, after treatment with raltegravir.36 HIV-1 IN sequence 
analysis of these resistant strains revealed the appearance of 
an identical pattern of nonpolymorphic mutations. N155H 
mutant was 14-fold less sensitive to raltegravir, while the 
sensitivity of E92Q and G140S/Q148H mutants was reduced 
by 7- to 8-fold. An important observation from these studies is 
that the risk of mutations and treatment failure with raltegravir 
seems to be increased in patients with a higher baseline 
HIV-1 RNA levels and lower CD4 cell counts. An earlier 
study had reported similar findings wherein sustained viral 
suppression was achieved in rhesus monkeys infected with 
simian-HIV, when treatment with IN inhibitor was initiated 
before CD4 cell depletion.37 Cellular immunity and initial 
viral load were thought to facilitate the therapeutic efficacy 
of the IN inhibitor. Such an association between raltegravir 
response rate, the baseline viral load and the CD4 count 
warrants further analysis.
Naturally occurring sequence variations in IN such as 
L74I, A91V, E92G are thought to be associated with the risk 
of drug resistance. While some of the secondary mutations 
associated with raltegravir resistance are found in inhibitor-
naïve populations, the major mutations (N155H, Q148K/H/R 
and E92Q) leading to high level resistance are infrequent.38,39 
No association between clade and frequency of occurrence 
of polymorphisms has been found. There was also only a 
minimal effect of clade-specific polymorphisms on raltegravir 
susceptibility.40
A better characterization of resistance development 
upon long-term clinical use of raltegravir is important. 
Time to viral suppression versus time to virologic failure 
due to emergence of resistance upon long-term treatment 
needs to be analyzed. In addition, many of the resistance 
mutations impair the catalytic activities of IN and affect 
the viral replication. Therefore, long-term efficacy data 
of raltegravir used in combination with other active 
antiretrovirals is required to evaluate the effect of such 
mutations on overall viral infectivity and to understand 
their impact on raltegravir efficacy. The efficacy of other 
IN inhibitors, which share a similar mechanism of action as 
raltegravir, would be affected because of cross-resistance.41 
However, the choice of the resistance pathway depends on 
the viral strain and the inhibitor. A recent study has suggested 
the use of a combination of IN strand transfer inhibitors to 
overcome the development of cross-resistance.42 Raltegravir 
acts by a distinct mechanism, different from that of other 
antiretrovirals, and it is likely to show no cross-resistance 
with other antiretrovirals in the treatment regimen. This 
would mean that HIV-1 viral strains resistant to raltegravir 
should still be susceptible to other classes of antiretrovirals 
and hopefully, to mechanistically different IN inhibitors.
Figure 3 Relative fold change in susceptibility to raltegravir.Core Evidence 2009:4 141
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Drug interactions with antiretrovirals
The current treatment paradigm involves coadministration 
of raltegravir along with other anti-HIV agents. The effects 
of coadministered drugs on raltegravir pharmacokinetics are 
summarized in Table 3. Raltegravir is primarily metabolized by 
UGT1A1. Atazanavir, a protease inhibitor, inhibits UGT1A1. 
Hence, coadministration with atazanavir can be expected 
to affect the drug levels of raltegravir. Pharmacokinetic 
data obtained from healthy volunteers indicate a moderate 
increase in plasma levels of raltegravir administered with 
atazanavir alone or in combination with ritonavir.43 Though 
coadministration with atazanavir resulted in increased plasma 
concentrations of raltegravir, no serious adverse effects or 
toxicities were reported in the study. Instead, this interaction 
could be favorable as it results in increased raltegravir trough 
concentrations. Another clinical study explored two-way 
pharmacokinetic interaction between atazanavir 300 mg, 
twice daily given along with raltegravir 400 mg, twice daily. 
Coadministration with raltegravir decreased the plasma 
drug levels of atazanavir. Raltegravir drug levels were also 
increased. Incidence of adverse events was similar in both 
treatment groups. Similar results were obtained for tenofovir 
disoproxil fumarate, another protease inhibitor that is also 
known to inhibit UGT1A1.44
Coadministration of other antiretrovirals such as ritonavir, 
lopinavir, tenofovir, etravirine, and efavirenz showed 
weak to moderate influence on the plasma concentrations 
and pharmacokinetic profile of raltegravir. None of these 
interactions were considered clinically significant. There 
has been a recent report of a potential interaction between 
raltegravir and tipranavir. Patients who switched from 
enfuvirtide to raltegravir, while also taking tipranavir/
ritonavir, developed hepatic cytolysis two weeks after 
initiating raltegravir treatment.45 By replacing tipranavir/
ritonavir with darunavir/ritonavir, their elevated liver 
function was restored to normal levels. The increase in 
tipranavir trough concentrations after raltegravir dosing has 
been attributed to a potential drug interaction.
Drug interactions with concomitant 
medications
Raltegravir does not induce or inhibit any of the cytochrome 
P450 enzymes. It had only a weak inhibitory effect on the 
seven different cytochrome enzymes, even at concentrations 
greater than 100 µM. It also did not induce cytochrome 
P450 3A4 at concentrations up to 10 µM. Coadministration 
of raltegravir with midazolam, a sensitive cytochrome 
P450 3A4 substrate, did not significantly affect the plasma 
pharmacokinetics of midazolam.46 On the other hand, strong 
inducers of UGT1A1 such as rifampin can be expected to 
reduce the plasma levels of raltegravir. Coadministration 
with rifampin decreased drug levels and peak concentrations 
significantly.47 A dose adjustment is recommended. 
Coadministration of raltegravir with oral contraceptives such 
as Ortho Tri-Cyclen (ethinyl estradiol/ norgestimate) did not 
have any clinically significant pharmacokinetic interactions.48 
Pharmacokinetics of raltegravir were found to be affected 
by omeprazole coadministration in healthy subjects in a 
phase I study.49 The plasma concentrations of raltegravir were 
increased with a 3–4-fold increase in AUC and Cmax. A possible 
mechanism for this observation involves an increase in gastric 
pH by omeprazole, causing increased solubility and absorption 
of raltegravir. This interaction however did not seem to have 
a clinically significant effect in HIV-1-infected patients. 
Therefore, no dose adjustments have been recommended for 
coadministration of raltegravir with omeprazole.
Serum lipids/dyslipidemia
The most common laboratory abnormalities in the raltegravir 
treatment group in treatment-experienced patients were 
increased serum cholesterol and triglyceride levels. These drug-
related increases in serum cholesterol and triglyceride levels 
were not associated with any lipid abnormalities.50 In comparison 
to efavirenz, raltegravir was found to be more lipid neutral.
Creatine kinase
Raltegravir also caused transient increases in serum creatine 
kinase, which were not considered significantly large. 
Patients at risk of muscle problems and renal failure have 
been recommended against using raltegravir. A case of severe 
rhabdomyolysis and acute worsening of renal insufficiency 
was reported in a 46-year-old patient initiated on raltegravir.51 
Further studies on raltegravir-associated rhabdomyolysis 
are warranted.
Cardiovascular effects
A double-blind, randomized, single-dose crossover study 
was conducted to assess the potential for a supratherapeutic 
dose of raltegravir to prolong the ventricular repolarization 
or QT/QTc interval. Administration of the supratherapeutic 
dose of 1600 mg of raltegravir was well tolerated and had no 
cardiac effects, such as prolongation of QT interval.52
Adverse events and tolerability
The safety and tolerability of raltegravir was assessed in 
the BENCHMRK trials. Overall, treatment with raltegravir Core Evidence 2009:4 142
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was well tolerated. The adverse events and their frequencies 
were comparable with the placebo-treated groups. The most 
common drug-related adverse events were diarrhea, nausea, 
headaches, and fatigue.25,53
Depression
A case report of exacerbation of pre-existing depression 
related with the initiation of raltegravir therapy in treatment-
experienced patients has been described.54 In addition to 
raltegravir and other antiretrovirals, these patients were also 
receiving treatment with antidepressants. Further studies 
are required to understand if this is a drug interaction with 
antidepressants, or a raltegravir-related effect.
incidence of malignancies and mortalities
An increase in the number of malignancies was observed in 
patients receiving raltegravir as compared to placebo recipients 
in the clinical trials. A relative risk of 4.26 for occurrence of 
cancer with raltegravir treatment versus comparator treatment 
has been reported. It is unclear whether this increased 
occurrence of cancer is drug-related or due to anticipated 
complications in such a patient population. Nine fatalities 
were reported in the BENCHMRK studies. These deaths were 
related to severe opportunistic infection and/or malignancy 
and were not drug-related. A comprehensive analysis of 
cancer rates in the five different randomized trials and an 
expanded access program has been reported.55 With up to 
48 weeks follow-up in clinical trials, cancer rates were found 
to be slightly lower for raltegravir. In open and expanded 
access settings with 24 weeks follow-up time, similar results 
for cancer rates were found. Overall, there seems to be no 
difference in risk for occurrence of cancer in HIV-1 patients 
receiving raltegravir or other antiretroviral agents.
Economic evidence
The wholesale acquisition cost of raltegravir (400 mg, twice 
daily, oral) is approximately US$27 per day or US$1,012.50 
for a 30-day supply. This is similar to or less than the 
acquisition costs of other recently approved antiretrovirals. 
Darunavir boosted with ritonavir (600 mg/100 mg, twice 
daily, oral) costs US$31 per day. Enfuvirtide (90 mg, twice 
daily, subcutaneous injection) costs US$81 per day.56
The cost-effectiveness of raltegravir in treatment-
experienced HIV-1 patients in Switzerland has been 
analyzed using a cohort-state transition model.57 The model 
classified patients according to their HIV-1 RNA level, 
CD4 cell count and presence of opportunistic infections 
combined with inputs from clinical trials and published 
reports. The model estimated an increase in discounted life 
expectancy by 3.5 years with raltegravir plus OBT treatment 
versus OBT alone. The incremental cost-effectiveness ratio 
for raltegravir plus OBT compared with OBT alone was 
US$2,1339 and US$45,077 per quality-adjusted life year 
gained for one- and five-year duration of raltegravir use, 
respectively. According to this study, addition of raltegravir 
to OBT results in substantial survival benefits and also proves 
to be a cost-effective option. In another cost–utility study 
conducted by Merck, the cost-effectiveness of raltegravir 
plus OBT was compared against OBT alone in patients with 
triple-class failure HIV-1 infection. Raltegravir plus OBT 
was associated with an incremental cost-effectiveness ratio 
of US$32,227 per quality-adjusted life year. In a secondary 
analysis, substituting raltegravir for tenofovir was associated 
with an incremental cost-effectiveness ratio of US$5,800 per 
quality-adjusted life year.56
There is only limited economic evidence regarding the 
cost-effectiveness of raltegravir compared to its comparators. 
The relative costs of raltegravir and etravirine in treating 
treatment-experienced HIV-1 patients have been compared in a 
cost-minimization analysis.58 Since no head-to-head comparison 
between raltegravir and etravirine exists, an indirect comparison 
at week 24 was made from the clinical outcomes of the DUET 
1&2 trials for etravirine and BENCHMRK 1&2 trials for 
raltegravir. Differences in OBT in these studies were accounted 
for. The efficacy and acquisition costs for each therapy to 
achieve viral load suppression to less than 50 copies/mL were 
analyzed. Both treatments demonstrated similar efficacy. The 
mean odd ratio versus placebo was 2.08 for etravirine and 1.92 
for raltegravir. Annual drug acquisition costs were US$7,957 
for etravirine and US$9,855 for raltegravir.
Extensive pharmacoeconomic studies in clinical practice 
are required to evaluate the cost-effectiveness of raltegravir 
treatment regimen in HIV-1 infected patients. There is no 
evidence to evaluate the potential impact of raltegravir use 
on health resource utilization.
Patient group/population
Raltegravir is currently approved for use in combination with 
other antiretroviral agents for the treatment of HIV-1 infection 
in treatment-experienced adult patients who show evidence 
of viral replication and multidrug-resistant HIV-1 viral 
strains. First-line treatment with raltegravir is not currently 
recommended.2
The following treatment guidelines have been provided 
regarding the use of raltegravir in HIV-1-infected patient 
population:Core Evidence 2009:4 144
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•  In treatment-naïve patients, safety and efficacy of 
raltegravir have not been established, and such use is 
currently not recommended.59,60
•  In pediatric patients and patients aged less than 16 years, 
safety and efficacy of raltegravir have not been established, 
and such use is currently not recommended.59,60
•  In HIV-1-infected patients misusing barbiturates, 
doubling the raltegravir dose has been recommended.61
•  In HIV-1 infected patients with tuberculosis, coadministration 
of rifampin reduces plasma concentrations of raltegravir. 
Recently, the Isentress® product label and package insert have 
been updated following its traditional approval by the US 
FDA. Increasing raltegravir dose to 800 mg twice daily during 
coadministration with rifampin has been recommended62 
Limited pharmacokinetic data is available regarding 
concomitant administration of rifabutin with raltegravir, and 
no such dose adjustments have been recommended.
Patients with hepatic impairment
An open-label, single dose, phase I study found no clinically 
important effect of moderate hepatic impairment on 
raltegravir pharmacokinetics.63 In this study, eight patients 
with chronic moderate hepatic impairment as defined by a 
Child–Pugh score of 7 to 9 and eight healthy, matched control 
subjects each received a single 400 mg dose of raltegravir. 
No clinically important differences in the pharmacokinetic 
parameters between the hepatic impaired group and healthy 
control group were observed. Results of this study indicate 
a low risk for reduced efficacy and reduced tolerability 
in patients with hepatic impairment. No dose adjustment 
is necessary for patients with mild to moderate hepatic 
impairment. No evidence is available on the pharmacokinetics 
of raltegravir in patients with severe hepatic impairment.
Patients with renal insufficiency
The effect of renal impairment on the pharmacokinetics of 
raltegravir was investigated in an open-label, single 400 mg 
dose, phase I study in 10 patients with severe renal insufficiency 
defined as a creatinine clearance of 30 mL/min per 1.73 m2 and 
10 healthy, matched control subjects. No clinically important 
differences in the pharmacokinetic parameters between the two 
groups were observed, though percent dose excreted in urine and 
renal clearance were considerably lower for patients with severe 
renal insufficiency. Also, since renal elimination of raltegravir 
is only modest, the results of this study can be extrapolated to 
patients with mild or moderate renal insufficiency including 
patients on dialysis. However, additional studies in patients 
undergoing dialysis may be required.63
Patients with hepatitis B or C virus  
co-infection
10%–20% of patients enrolled in the BENCHMRK 1&2 
studies were co-infected with hepatitis B or C virus.23 
In patients with hepatitis B or C virus co-infection, the 
safety profile of raltegravir was similar to that in patients 
without co-infection. The rate of laboratory abnormalities 
from baseline alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST), or total bilirubin was higher in 
patients with hepatitis B or C virus co-infected in raltegravir 
as well as placebo treatment groups.
Patients with risk of myopathy  
and rhabdomyolysis
Adverse events such as myopathy and rhabdomyolysis have 
been reported with use of raltegravir. In patients at increased 
risk of myopathy and rhabdomyolysis such as patients 
receiving concomitant medications known to cause these 
conditions, raltegravir must be used with caution.
Dosage, administration, and formulations
Raltegravir (Isentress®), in combination with other anti-
retroviral agents, is indicated for the treatment of HIV-1 
infection in treatment-experienced adult patients who have 
evidence of viral replication and drug-resistant HIV-1 viral 
strains. It is formulated as its potassium salt and is available 
as film-coated tablets containing 434.4 mg of raltegravir 
potassium or 400 mg equivalent of raltegravir. The current 
prescribed dosing is 400 mg taken orally, twice daily 
without any dietary restrictions. Boosting with ritonavir is 
not required. Raltegravir is not metabolized by cytochrome 
P450 enzymes and does not have significant drug interactions. 
Hence, no dose adjustment has been recommended when 
coadministered with other antiretroviral agents. However, 
during coadministration with rifampin, 800 mg raltegravir 
twice daily is recommended.62
Place in therapy
As the first member of the new class, raltegravir has 
established the clinical potential of IN inhibitors in the 
treatment of HIV-1 infection. Raltegravir has demonstrated 
substantial clinical efficacy in treatment-experienced 
HIV-1 patients. Key evidence relating to disease-oriented and 
patient-oriented outcomes are summarized in the evidence 
summary table. There is strong evidence that raltegravir 
can achieve significant and sustained suppression of viral 
RNA levels to less than 50 copies/mL and substantial Core Evidence 2009:4 145
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immune response in drug-resistant HIV-1 patients. This 
offers the much needed alternative salvage therapy to 
HIV-1 infected patients faced with drug resistance and 
failure of first-line antiretroviral regimen. Treatment with 
raltegravir has been found to be well tolerated with good 
safety and minimal toxicity. Drug interactions with most 
other antiretroviral agents and concomitant medications did 
not have clinical significance. Dose-adjustment has been 
recommended during concomitant use with rifampin. There 
is insufficient data regarding other patient-oriented outcomes, 
such as improvement in quality of life, improvement in 
patient compliance and adherence to treatment, improvement 
in morbidity and mortality.
Since raltegravir acts selectively on HIV IN, there is no 
risk of developing cross-resistance against other classes of 
antiretrovirals. However, the high propensity for development 
of resistance mutations may undermine the therapeutic 
benefit of raltegravir. Hence, raltegravir should be used 
in combination with at least one other active drug. There 
is also high probability of cross-resistance against other 
mechanistically similar IN inhibitors. Future efforts on 
developing second generation IN inhibitors should be directed 
against overcoming the challenge of therapeutic resistance.
There is limited economic evidence regarding the use of 
raltegravir. However, preliminary analysis of the acquisition 
cost and cost-effectiveness estimate an incremental 
cost-effectiveness ratio for raltegravir at $US21339 per 
quality-adjusted life year gained. Direct evidence from studies 
evaluating the cost-effectiveness in a combination therapy is 
needed to confirm the economic benefits of raltegravir.
In summary, there is strong evidence that treatment 
with raltegravir in treatment-experienced patients results 
in sustained suppression of viremia to less than 50 HIV-1 
RNA copies per milliliter accompanied with improvement 
in immunologic response. Substantial evidence also show 
that raltegravir has no significant interactions with other 
antiretrovirals and concomitant medications and has a good 
safety and tolerability profile.
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